CMA vs RAPP
CMA (CMA) versus Rapport Therapeutics, Inc. Common Stock (RAPP) — a side-by-side from cached financials, not a winner call.
CMA (CMA) common stock.
Rapport Therapeutics, Inc. Common Stock (RAPP) is a biotechnology company listed on US.
CMA does not have a complete income-statement cache yet.
Latest reported RAPP revenue for 2026-06-30 was $20.0M. Net income was -$76.5M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. RAPP currently screens at market cap $532.9M.
RAPP currently screens at market cap $532.9M.
Not investment advice. Open the CMA and RAPP stock pages for the full models.
Not investment advice.